PubMed:23704121 JSONTXT

{"project":"bionlp-st-bb3-2016-training","denotations":[{"id":"T1","span":{"begin":0,"end":52},"obj":"Title"},{"id":"T2","span":{"begin":65,"end":321},"obj":"Paragraph"},{"id":"T3","span":{"begin":331,"end":624},"obj":"Paragraph"},{"id":"T4","span":{"begin":634,"end":1274},"obj":"Paragraph"},{"id":"T5","span":{"begin":1288,"end":1571},"obj":"Paragraph"},{"id":"T6","span":{"begin":153,"end":174},"obj":"Bacteria"}],"text":"Is fidaxomicin worth the cost? An economic analysis.\nBACKGROUND: In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined.\nMETHODS: We developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results.\nRESULTS: The incremental cost-effectiveness ratio for fidaxomicin based on screening given current conditions was \u003e$43.7 million per quality-adjusted life-year and using only fidaxomicin was dominated (ie, more costly and less effective) by the other 2 treatment strategies explored. The fidaxomicin strategy tended to remain dominated, even at lower costs. With approximately 50% of CDI due to the NAP1/BI/027 strain, a course of fidaxomicin would need to cost ≤$150 to be cost-effective in the treatment of all CDI cases and between $160 and $400 to be cost-effective for those with a non-NAP1/BI/027 strain (ie, treatment based on strain typing).\nCONCLUSIONS: Given the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin."}

{"project":"Allie","denotations":[{"id":"SS1_23704121_3_0","span":{"begin":153,"end":184},"obj":"expanded"},{"id":"SS2_23704121_3_0","span":{"begin":186,"end":189},"obj":"abbr"}],"relations":[{"id":"AE1_23704121_3_0","pred":"abbreviatedTo","subj":"SS1_23704121_3_0","obj":"SS2_23704121_3_0"}],"text":"Is fidaxomicin worth the cost? An economic analysis.\nBACKGROUND: In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined.\nMETHODS: We developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results.\nRESULTS: The incremental cost-effectiveness ratio for fidaxomicin based on screening given current conditions was \u003e$43.7 million per quality-adjusted life-year and using only fidaxomicin was dominated (ie, more costly and less effective) by the other 2 treatment strategies explored. The fidaxomicin strategy tended to remain dominated, even at lower costs. With approximately 50% of CDI due to the NAP1/BI/027 strain, a course of fidaxomicin would need to cost ≤$150 to be cost-effective in the treatment of all CDI cases and between $160 and $400 to be cost-effective for those with a non-NAP1/BI/027 strain (ie, treatment based on strain typing).\nCONCLUSIONS: Given the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin."}